p38 MAPK Activator

Acanthoic acid (NP1302) is an orally active pimarane-type diterpenoid. Acanthoic acid is isolated from the root bark of Araliaceae family plant Eleutherococcus senticosus (Siberian ginseng). Acanthoic acid activates LXR and FXR. Acanthoic acid activates the AMPK-LKB1, SIRT1, and p38 MAPK signaling pathways and increases the phosphorylation level of ACC. Acanthoic acid downregulates the expression of SREBP-1, CYP2E1, HIF-1α, and PPARγ, and upregulates the expression of PPARα. Acanthoic acid induces Apoptosis by activating Caspase-3, promoting PARP cleavage, and downregulating Bcl-xL. Acanthoic acid exhibits antioxidant, anti-fibrotic, and hepatoprotective effects. It reduces lipid accumulation and lipogenesis. Acanthoic acid is used in studies on non-alcoholic fatty liver disease, alcoholic liver disease, acute promyelocytic leukemia, and Acetaminophen-induced hepatotoxicity.

C16-PAF (Standard) is the analytical standard of C16-PAF. This product is intended for research and analytical applications. C16-PAF (PAF (C16)), a phospholipid mediator, is a platelet-activating factor and ligand for PAF G-protein-coupled receptor (PAFR). C16-PAF exhibits anti-apoptotic effect and inhibits caspase-dependent death by activating the PAFR. C16-PAF is a potent MAPK and MEK/ERK activator. C16-PAF induces increased vascular permeability.

GO-Y078 is a curcumin (HY-N0005) analog. GO-Y078 activates p38/JNK1/2. GO-Y078 activates the MAPK pathway, Caspase 3/8/9, PARP, AP-1, DR5, and TP53, while inhibiting cIAP-1, XIAP, and NF-κB. GO-Y078 induces sub-G₁/G₂/M phase arrest and Apoptosis. GO-Y078 impairs angiogenesis. GO-Y078 can be used in research related to osteosarcoma, cervical cancer, oral squamous cell carcinoma, and peritoneal metastasis of gastric cancer.

Lambertellin is an effective antibiotic that can be used as a bactericide and as a fungicide. Lambertellin exerts its anti-inflammatory effect in LPS (HY-D1056)-stimulated RAW 264.7 macrophage cells by modulating the activation of the MAPK and NF-κB signaling pathways.

3-AP-Me is a dimethyl derivative of the nucleotide reductase inhibitor 3-AP (SML0568). 3-AP-Me can activate the endoplasmic reticulum (ER) stress pathway by promoting the phosphorylation of eIF2α and increasing the gene expression of transcription factors ATF4 and ATF6, leading to cell apoptosis. Additionally, 3-AP-Me can activate the stress kinases c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinases. 3-AP-Me also leads to the upregulation of the spliced mRNA variant XBP1, can be used in cancer research.

Complex I-IN-1 is a novel fungicide that acts as a mitochondrial complex I inhibitor. Complex I-IN-1 regulates oxidoreductase activity, glycolysis/gluconeogenesis, methionine metabolism, and the MAPK signaling pathway in Blumeria graminis. Complex I-IN-1 is applicable to research related to wheat powdery mildew.

Norflurazon (Standard) (SAN 9789 (Standard)) is the analytical standard of Norflurazon (HY-114849). This product is intended for research and analytical applications. Norflurazon (SAN 9789) is a pre-emergence Herbicide. Norflurazon non-competitively inhibits phytoene desaturase by competing with the enzyme cofactor and disrupts carotenoid biosynthesis, thereby leading to chlorophyll photodegradation and chlorosis. Norflurazon inhibits MGDG synthase, CDP-choline phosphotransferase, Omega-3 FAD7 desaturase, and PG delta-3-trans desaturase, and activates LysoPC-acyltransferase and Omega-3 FAD3 desaturase. Norflurazon inhibits photosynthetic membrane organization, mitochondrial respiration, ATP production, PI3K signaling, and ERK1/2 phosphorylation. Norflurazon activates MAPK P38 phosphorylation and ER stress signaling. Norflurazon induces morphological malformations and cardiovascular effects in zebrafish embryos.

2-Hydroxy-5-(2-nitrovinyl) benzoic acid (SANA) is an orally active pleiotropic anti-inflammatory metabolic modulator. 2-Hydroxy-5-(2-nitrovinyl) benzoic acid inhibits NF-κB, activates Nrf2/Keap1 and AMPK, suppresses inflammasome activity, induces thermogenesis, reverses insulin resistance and alleviates skin graft rejection. 2-Hydroxy-5-(2-nitrovinyl) benzoic acid can be used in research related to obesity, glucose intolerance, skin graft rejection and insulin resistance.

Iroxanadine hydrobromide (BRX 005) is a vasculoprotector. Iroxanadine is a p38 kinase and HSP protein dual activator. Iroxanadine hydrobromide has the potential for atherosclerosis and vascular diseases research.

Iroxanadine (BRX 005) is a vasculoprotector. Iroxanadine is a p38 kinase and HSP protein dual activator. Iroxanadine has the potential for atherosclerosis and vascular diseases research.

Ethalfluralin is a dinitroaniline herbicide and microtubule inhibitor. Ethalfluralin blocks nuclear division and cytokinesis of parasites by inhibiting intranuclear spindle formation. Ethalfluralin activates the phosphorylation levels of NF-κB and P38 MAPK, inhibits the PI3K/AKT signaling pathway, impairs mitochondrial function, and induces apoptosis, endoplasmic reticulum stress, autophagy, and ROS production. Ethalfluralin is applicable to research related to toxoplasmosis.

Vinburnine ((-)-Eburnamonine; (-)-Vincamone) (Standard) is the analytical standard of Vinburnine (HY-B1180). This product is intended for research and analytical applications. Vinburnine ((-)-Eburnamonine; (-)-Vincamone) phosphate is an orally active, blood-brain barrier permeable immunomodulator and apoptosis inducer. Vinburnine drives the secretion of IL-24 by activating the P38/MAPK/ATF3 signaling axis. Vinburnine induces reactive oxygen species production and DNA damage in cancer cells, thereby inhibiting cancer cell proliferation, activating the apoptotic cascade, and enhancing CD8+ T cell function to remodel the tumor immune microenvironment. Vinburnine can be used in the research of diseases such as melanoma.

Vinburnine ((-)-Eburnamonine; (-)-Vincamone) phosphate is an orally active, blood-brain barrier permeable immunomodulator and apoptosis inducer. Vinburnine phosphate drives the secretion of IL-24 by activating the P38/MAPK/ATF3 signaling axis. Vinburnine phosphate induces reactive oxygen species production and DNA damage in cancer cells, thereby inhibiting cancer cell proliferation, activating the apoptotic cascade, and enhancing CD8+ T cell function to remodel the tumor immune microenvironment. Vinburnine phosphate can be used in the research of diseases such as melanoma.

MptpB-IN-3 is a selective inhibitor of Mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB) with an IC₅₀ of 0.19 μM. MptpB-IN-3 blocks MptpB-mediated inhibition of the macrophage MAPK pathway and restores the phosphorylation levels of Erk1/2 and p38. MptpB-IN-3 exhibits direct anti-tuberculosis activity against Mycobacterium tuberculosis and reduces the Mycobacterium tuberculosis load in mouse macrophages. MptpB-IN-3 can be used for tuberculosis research.

A1-Phytoprostane-I (Phytoprostane A1) is a cyclopentenone-type phytoprostane that forms via free radical-catalyzed non-enzymatic oxidation of α-linolenic acid. A1-Phytoprostane-I exhibits multiple biological activities, including inducing the accumulation of phytoalexins (e.g., Scopoletin (HY-N0342)) in tobacco cells, activating mitogen-activated protein kinases (MAPK) in tomato cells, and inducing the expression of glutathione-S-transferase 1 (Glutathione-S-transferase 1) in Arabidopsis thaliana.

Sudachitin is an orally active compound that potently inhibits mouse PDE1C and human PDE4B, with IC₅₀ values of 5.0 μM and 15.0 μM, respectively. Sudachitin upregulates Sirt1 and PGC‑1α expression in skeletal muscle to regulate energy metabolism and promote mitochondrial biogenesis. Sudachitin improves lipid metabolism, glucose tolerance, insulin sensitivity, energy expenditure, and fatty acid β‑oxidation. Sudachitin activates p38MAPK signaling, induces HSP27 phosphorylation and caspase‑dependent apoptosis, and blocks EGF‑driven keratinocyte migration and proliferation. Sudachitin suppresses LPS‑induced TNF‑α, NO, and iNOS expression in macrophages and shows potent anti‑inflammatory activity. Sudachitin can be used for the research of metabolic syndrome, type 2 diabetes, and psoriasis..

L-Ornithine-1,2-¹³C₂ hydrochloride is the ¹³C-labeled L-Ornithine hydrochloride (HY-W017018). L-Ornithine hydrochloride is an orally active CaSR and p38 activator. L-Ornithine hydrochloride inhibits ROS and supports urea cycle function. L-Ornithine hydrochloride can be used to study kidney diseases involving proximal tubular cell damage caused by oxidative stress or crystallopathy, as well as research related to anxiety disorders.

(Z)-Tetradec-7-en-1-ol is an activator for mitogen-activated protein kinase (MAP kinase).

Phaeosphaeride A is a STAT3 inhibitor with an IC₅₀ of 0.61 mM against human STAT3. It exhibits higher selectivity for STAT3 over STAT1 and STAT5. Phaeosphaeride A inhibits the binding of STAT3 to DNA, STAT3-dependent transcriptional activity, as well as IL-6-induced phosphorylation and signaling of STAT3. Phaeosphaeride A activates the JNK, p38, Akt, CREB and STAT5A/B signaling pathways. Phaeosphaeride A induces oxidative stress (ROS), exerts antiproliferative and growth-inhibitory effects in cancer cells, and shows low cytotoxicity toward non-cancerous cells. Phaeosphaeride A is a phytotoxin and a weak animal toxin, with no antimicrobial activity against tested bacteria and fungi. Phaeosphaeride A can be used in research related to conditions such as cervical cancer and multiple myeloma, as well as weed infestations.

Neomangiferin (Standard) is the analytical standard of Neomangiferin. This product is intended for research and analytical applications. Neomangiferin is an orally active natural flavonoid. Neomangiferin partially ameliorates non-alcoholic fatty liver disease (NAFLD) by regulating the expression of genes related to free fatty acid uptake and lipid oxidation. Neomangiferin exerts anti-colitis effects by inhibiting Th17/Treg cell differentiation. Neomangiferin exerts anti-aging and lifespan-extending effects by targeting upregulation of bas-1, which in turn activates the autophagy, IIS and MAPK pathways. Neomangiferin has the potential to prevent aseptic loosening of prostheses after total joint arthroplasty due to its significant anti-inflammatory and osteoclastogenesis-inhibiting effects.